DMD Simcyp

Home Help [Feedback] [For Subscribers] [Archive] [Search] --
 QUICK SEARCH:   [advanced]


     


Drug Metabolism and Disposition Fast Forward
First published on May 27, 2008; DOI: 10.1124/dmd.108.020701


This Article
Right arrow Full Text (PDF)
Right arrow Data Supplement
Right arrow All Versions of this Article:
dmd.108.020701v1
36/8/1689    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Yasuda, K.
Right arrow Articles by Bachmann, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Yasuda, K.
Right arrow Articles by Bachmann, K.


Received for publication January 31, 2008.
Revised May 16, 2008.
Accepted for publication May 19, 2008.

A Comprehensive in vitro and in silico Analysis of Antibiotics that Activate PXR and Induce CYP3A4 in Liver and Intestine

Kazuto Yasuda 1, Aarati Ranade 2, Raman Venkataramanan 3, Stephen Strom 4, Jonathan Chupka 5, Sean Ekins 6, Erin Schuetz 7, Kenneth Bachmann 5*

1 Deptartment of Pharmaceutical Sciences,St Jude Children's Research Hospital, Memphis, TN 2 Department of Pharmaceutical Sciences, School of Pharmacy, University of Pittsburgh, Pittsburgh PA 3 Department of Pharmaceutical Sciences, School of Pharmacy, University of Pittsburgh 4 Department of Pharmaceutical Sciences, School of Pharmacy, University of Pittsburgh, Pittsburgh, PA 5 Department of Pharmacology, The University of Toledo College of Pharmacy, Toledo, OH 6 Collaborations in Chemistry, Jenkintown PA 7 Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, TN

* Address correspondence to: E-mail: kbachma{at}utnet.utoledo.edu

Abstract

We have investigated several in silico and in vitro methods in order to improve our ability to predict potential drug interactions of antibiotics. Our focus was to identify those antibiotics that activate PXR and induce CYP3A4 in human hepatocytes and intestinal cells. Human PXR activation was screened using reporter assays in HepG2 cells, kinetic measurements of PXR activation were made in DPX-2 cells, and induction of CYP3A4 expression and activity was verified by quantitative PCR, immunoblotting and testosterone 6â-hydroxylation in primary human hepatocytes and LS180 cells. We found that in HepG2 cells CYP3A4 transcription was activated strongly (>10-fold) by rifampin and troleandomycin; moderately (> 7-fold) by dicloxacillin, tetracycline, clindamycin, griseofulvin and (> 4-fold) by erythromycin; weakly (>2.4-fold) by nafcillin, cefaclor and sulfisoxazole; and (>2-fold) by cefadroxil and penicillin V. Similar though not identical results were obtained in DPX-2 cells. CYP3A4 mRNA and protein expression were induced by these antibiotics to differing extents in both liver and intestinal cells. CYP3A4 activity was significantly increased by rifampin (9.7-fold), nafcillin and dicloxacillin (5.9-fold), and weakly induced (2-fold) by tetracycline, sufisoxazole, troleandomycin and clindamycin. Multiple pharmacophore models and docking indicated a good fit for dicloxacillin and nafcillin in PXR. These results suggest that in vitro and in silico methods can help to prioritize and identify antibiotics that are most likely to reduce exposures of medications (such as oral contraceptive agents) which interact with enzymes and transporters regulated by PXR. In summary, nafcillin, dicloxacillin, cephradine, tetracycline, sulfixoxazole, erythromycin, clindamycin, and griseofulvin exhibit a clear propensity to induce CYP3A4 and warrant further clinical investigation.


Key words: antibiotics, CYP induction, CYP3A, drug-drug interactions, enzyme induction, hepatocytes, isolated hepatocytes, PXR


This article has been cited by other articles:


Home page
Drug Metab. Dispos.Home page
Y. S. Lin, K. Yasuda, M. Assem, C. Cline, J. Barber, C.-W. Li, V. Kholodovych, N. Ai, J. D. Chen, W. J. Welsh, et al.
The Major Human Pregnane X Receptor (PXR) Splice Variant, PXR.2, Exhibits Significantly Diminished Ligand-Activated Transcriptional Regulation
Drug Metab. Dispos., June 1, 2009; 37(6): 1295 - 1304.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] --
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2008 by the American Society for Pharmacology and Experimental Therapeutics.